Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal
Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
Complete response is a rare event in metastatic anal cancer in the case of unresectable
recurrence after radiochemotherapy.
In the University Hospital Center of Besançon, 8 patients with metastatic anal cancer were
treated between 2005 and 2008 by 6 cycles of chemotherapy including taxane: DCF (Docetaxel,
Cisplatin and 5-Fluorouracil.
In more than 90% of cases, anal cancers are related to Human Papilloma Virus (HPV) infection,
that is the case of this patients for which HPV16 (human papillomavirus type 16) genotype was
identified within the tumor samples.
The hypothesis is that an anti-HPV response immune could be generated by chemotherapy with
DCF and contributed to the elimination of the tumour cells and to the increase of complete
responses. The aim to this study is to analyze immune response against HPV in this patients
in complete response.